Key Drivers
- Balance Sheet
- Cash Burn
- No Revenue
AIAI Summary
DYN has shifted from a pure cash-burn biotech to a near-term catalyst story with a strong balance sheet, but the stock now hinges on a narrow set of binary outcomes—especially FDA approval and launch execution for z-rostudirsen—while heavy burn means any delay could quickly reopen financing risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Balance Sheet
- •Cash Burn
- •No Revenue
DYN has a very strong balance sheet and ample liquidity, but ongoing pre-revenue losses and heavy cash burn continue to erode equity and make the stock's ~3.5x book valuation hard to justify.
Price Behavior
Key Price Behavior Insights:
- •Last-month uptrend
- •Near-term support
- •Stretch risk
DYN remains in a strong last-month uptrend with higher highs and higher lows, but after a sharp rally to $23.07 it is short-term extended near resistance, with $21.26–$21.79 as near-term support and a breakout above $23.07 needed to confirm continuation.
Sharp rally from $17.99 to $23.07 suggests momentum is strong but extended
Sentiment & News
Key News Insights:
- •Debt flexibility
- •Talent expansion
- •Board strength
Dyne Therapeutics strengthened its balance sheet, added leadership and talent, and remains positioned as a differentiated rare-disease biotech amid improving sector sentiment and peer comparisons.
These updates are modestly positive for Dyne, supporting execution and financial runway while keeping attention on its pipeline progress versus larger biotech peers
Similar Companies in Healthcare
Other companies in the same sector with AI ratings